Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Future of Incretin-Based Approaches for Neurodegenerative Diseases in Older Adults: Which to Choose? A Review of their Potential Efficacy and Suitability
Christine Girges, Nirosen Vijiaratnam, Dilan Athauda, et al.
Drugs & Aging (2021) Vol. 38, Iss. 5, pp. 355-373
Open Access | Times Cited: 12

Showing 12 citing articles:

Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease
Joseph Nowell, Eleanor G Blunt, Dhruv Gupta, et al.
Ageing Research Reviews (2023) Vol. 89, pp. 101979-101979
Open Access | Times Cited: 79
Incretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease
Joseph Nowell, Eleanor G Blunt, Paul Edison
Molecular Psychiatry (2022) Vol. 28, Iss. 1, pp. 217-229
Open Access | Times Cited: 66
DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson’s disease
Seong‐Jin Yu, Yun Wang, Hui Shen, et al.
GeroScience (2024) Vol. 46, Iss. 5, pp. 4349-4371
Open Access | Times Cited: 10
Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives
Federica Ferrari, Antonio Moretti, R. F. Villa
Pharmacology & Therapeutics (2022) Vol. 239, pp. 108277-108277
Closed Access | Times Cited: 32
How should we be using biomarkers in trials of disease modification in Parkinson’s disease?
Nirosen Vijiaratnam, Thomas Foltynie
Brain (2023) Vol. 146, Iss. 12, pp. 4845-4869
Open Access | Times Cited: 21
Metabolic hormones are integral regulators of female reproductive health and function
Faria Athar, M. Karmani, Nicole M. Templeman
Bioscience Reports (2023) Vol. 44, Iss. 1
Open Access | Times Cited: 16
Glucagon-like peptide-1 receptor agonists for major neurocognitive disorders
Riccardo De Giorgi, Ana Ghenciulescu, Courtney Yotter, et al.
Journal of Neurology Neurosurgery & Psychiatry (2025), pp. jnnp-335593
Closed Access
Nanotechnology-Based Drug Delivery Strategies to Repair the Mitochondrial Function in Neuroinflammatory and Neurodegenerative Diseases
Luis F. González, Lorenzo E. Bevilacqua, Rodrigo Naves
Pharmaceutics (2021) Vol. 13, Iss. 12, pp. 2055-2055
Open Access | Times Cited: 16
GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression
Dilan Athauda, James R. Evans, Laura Mahoney‐Sanchez, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Disease modifying therapies for Parkinson's disease: Novel targets
Nirosen Vijiaratnam, Thomas Foltynie
Neuropharmacology (2021) Vol. 201, pp. 108839-108839
Closed Access | Times Cited: 4
Management of Diabetes Mellitus by Nano Based Drug Delivery with Special Reference to Phytosomes
Jiyauddin Khan, Abu Md Ashif Ikbal, Bikash Debnath, et al.
Pharmaceutical and Biosciences Journal (2021), pp. 11-28
Open Access | Times Cited: 4
Incretin-Based Therapies: A Promising Approach for Modulating Oxidative Stress and Insulin Resistance in Sarcopenia
Raniah I. Alnaser, Fawaz A. Alassaf, Mohammed N. Abed
Journal of Bone Metabolism (2024)
Open Access
Page 1

Scroll to top